ALVAIZ

Growth

eltrombopag

Teva

NDAORALTABLET

Approved

Nov 2023

Lifecycle

Growth

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.

Indications (10)

thrombocytopenia in adult older with persistent chronic immune thrombocytopenia (ITP)immunoglobulins splenectomy thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation maintenance of interferon-based therapy hepatitis C anemia for the treatment of thrombocytopenia

Clinical Trials (5)

NCT05961410Phase 2Recruiting

Eltrombopag for Peripheral Blood Stem Cell Harvest

Started Aug 2023

46 enrolled

LymphomaPeripheral Blood Stem Cell Transplantation

NCT07415083N/ACompleted

A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia

Started Jun 2023

13 enrolled

Aplastic Anemia

NCT06768619N/ACompleted

Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State

Started Mar 2023

NCT05653219Phase 3Active Not Recruiting

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Started Feb 2023

152 enrolled

Primary Immune Thrombocytopenia

NCT04812483Phase 2Completed